Prevention Of Morbidity In Sickle cell disease pilot phase

Institute of Child Health (UK)0 个研究点目标入组 22 人开始时间: 2007年1月12日最近更新: 2019年10月7日

适应症

试验速览

•1. Age more than four years old
•2. Informed consent with assent in accordance with UK ethical committee (Central Office for Research Ethics Committees [COREC]) system must be signed by the patient's parent or legally authorised guardian acknowledging written consent to join the study. When suitable, patients will be requested to give their assent to join the study
•3. Haemoglobin SS (homozygous sickle cell anaemia) diagnosed by standard techniques. Participating institutions must submit documentation of the diagnostic haemoglobin analysis

•1. Existing respiratory failure
•2. Decompensated cardiac failure
•3. History of severe epistaxis
•4. Trans-sphenoidal surgery, or trauma that could have left a cranio-nasopharyngeal fistula
•5. Perforated ear drum
•6. Bullous lung disease
•7. Bypassed upper airway
•8. Pneumothorax
•9. Pathologically low blood pressure
•10. Cerebral Spinal Fluid (CSF) leaks, abnormalities of the cribriform plate, prior history of head trauma, and/or pneumocephalus
•11. Patients on chronic regular blood transfusion
•12. Patient who received treatment with anti-sickling drugs or hydroxyurea within three months
•13. Patient with other neurological problems, such as neurofibromatosis, lead poisoning, or tuberous sclerosis
•14. Pregnancy
•15. Sinus or middle ear infection (temporary)

发起方

Institute of Child Health (UK)